Lowest Price Guaranteed
Pages
450
Last Updated
May 2026
View Count
26508
The targeted protein degradation market is estimated to grow from USD 0.48 billion in 2024 to reach USD 1.00 billion in 2025 and USD 6.94 billion by 2035, representing a higher CAGR of 21% during the forecast period.
 |
To learn more about this report, request a free sample copy
Targeted protein degradation (TPD) is a therapeutic strategy that harnesses the cell’s own protein degradation machinery to selectively eliminate disease causing proteins, fundamentally differing from traditional therapies that merely inhibit protein function.
Over the years, conventional drug discovery approaches, such as small molecule inhibitors, focused on inhibiting the activity of particular protein to relieve disease symptoms, have faced several challenges. However, with increasing understanding of cellular mechanisms and proteomics, researchers have developed an unconventional approach; targeted protein degraders go beyond inhibition and serve as a promising alternative in the quest for more effective therapies.
In addition, scientists refer to the modalities that break down proteins as targeted protein degraders. These protein degraders are bifunctional small molecules that recruit E3 ubiquitin ligases to the protein of interest and mediate its ubiquitination and subsequent proteolysis by the proteasome, thereby degrading a specific protein. This process is robust, more sensitive, and can regulate cellular functions effectively, since it does not depend on attachment to other sites.
| Key Report Attributes | Details | |
| Historical Trend | Since 2023 | |
| Forecast Period | Till 2035 | |
| Market Size in 2025 | $1.00 Billion | |
| Market Size in 2035 | $6.94 Billion | |
| CAGR (Till 2035) | 21% | |
The global targeted protein degradation market analysis also features the likely distribution of the current and forecasted opportunity within the sustainable packaging domain across various segments, such as type of degrader, target indication, geographical regions, and sales forecast.
We have created three market forecast scenarios, conservative, base and optimistic, to account for future uncertainties in key parameters and enhance the robustness of our model. These scenarios represent different tracks of the industry's evolution.
Further, in recent years, targeted protein degraders have emerged as a popular therapeutic modality due to the various advantages offered by them, including specificity, stability and minimal off-side effects. Additionally, it is worth noting that these degraders offer broad applicability and can gain selectivity for their protein targets by optimizing the linker length and stabilizing the ternary complexes.
Several recent developments in the field of targeted protein degradation therapies have occurred, and we outline some of these below. These developments, even if they arose after our market report’s release, support the overall targeted protein degradation market trends detailed in our analysis.
The market research report presents an in-depth analysis of the various leading companies in protein degradation market, across different segments, as defined in the table below:
| Market Segmentations | Details | |
| Type of Degrader |
|
|
| Target Indication |
|
|
| Geographical Regions |
|
|
| Market in North America |
|
|
| Market in Europe |
|
|
| Market in Asia-Pacific |
|
|
| Market in Rest of the World |
|
|
Several start-ups and big pharma players have entered the targeted protein degradation drug market and now offer novel targeted protein degradation technologies, leading to the development of more potent, pharmacologically distinct, and target-specific degraders. As the demand for selective and efficacious treatments continues to grow, experts expect the targeted protein degradation market to experience substantial growth during the forecast period.
Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes detailed transcripts of interviews conducted with the following individuals:
Targeted protein degradation domain will mark a turning point in 2025. Anne Kerber, (Senior Vice President, Head of Development, Hematology, Oncology and Cell Therapy, Bristol Myers Squibb), states, “As a leader in the field of targeted protein degradation, we are committed to applying our decades of expertise to the development of these next wave of agents. The efficacy and safety data presented at the EHA Annual Meeting this year is promising and reinforces the potential of CELMoD agents in combination with other standard treatments.”
| Report Deliverables | Details | |
| Excel Data Packs (Complimentary) |
|
|
| Key Targeted Protein Degradation Companies Profiled |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
The “Targeted Protein Degradation Market: Industry Trends and Global Forecasts, till 2035” market report features an extensive study of the current market landscape (therapies and technologies), clinical trial analysis, grants analysis, funding and investment analysis, partnerships and collaborations, patent analysis, publication analysis and market size and future opportunities (therapies and technologies) within the targeted protein degradation industry, during the forecast period.
Currently, over 90 drug developers are involved in the development of targeted protein degradation therapies for various oncological indications, especially breast cancer, solid tumor and prostate cancer. The market landscape features a mix of large, mid-sized and small firms.
Additionally, players, such as Arvinas, Monte Rosa Therapeutics and Lycia Therapeutics are revolutionizing the targeted protein degradation therapies research and development, driving impactful innovations in the healthcare domain.
Presently, around 80 companies are offering various novel and advanced targeted protein degradation technologies. Researchers are actively developing degraders such as PROTACs, molecular glues, DUB inhibitors, bifunctional degraders, LYTACs, antibody drug conjugate-based degraders, and monovalent degraders with the help of these technologies.
It is worth mentioning that some companies use advanced tools, such as CADD, to design and analyze the 3D structure of proteins, leading to the development of more precise and potent degraders. Notably, targeted protein degradation technologies will play a significant role in shaping the future market landscape by enabling the development of novel therapeutic modalities for targets that were previously considered undruggable.
The global targeted protein degradation market size is likely to be worth $ 1.00 billion in 2025 and will reach $ 6.94 billion by 2035. In terms of the type of degrader, SERDs holds the largest share of the targeted protein degradation market forecast, in 2025. The market size for PROTACs is likely to grow at a relatively higher CAGR of 28% during the forecast period.
North American companies will likely dominate the global targeted protein degradation market in 2035. Presently, North America captures the majority (~85%) of the market share, and this trend is unlikely to change in the future. This is due to a number of factors contributing to the region’s dominance in this industry which include the presence of several well-established and big pharma companies with diverse experience in research and development of drugs.
The market in Asia-Pacific is likely to grow at a relatively high CAGR, during the forecast period till 2035. This can be likely due to the likely approval of several degraders and affordable price of treatments in this region.
The rising incidence of cancer has driven researchers and pharmaceutical companies to develop novel entities for cancer treatment. As a result, various stakeholders are actively evaluating different types of modalities. One such modality, targeted protein degraders, has shown strong potential for the treatment of oncological indications. Ongoing technological advancements in novel PROTAC platforms and molecular glue technologies are paving the way for the development of precise and stable degraders.
Additionally, targeted protein degraders can selectively modulate complex undruggable targets by harnessing the cell’s own machinery, which is driving the targeted protein degradation market growth. Furthermore, researchers can formulate most degraders as oral medications, making them easy for patients to take and encouraging greater adoption of these therapies in the coming years.
The ability of targeted protein degraders to selectively degrade undruggable targets while minimizing off-site toxicity and offering broad applicability is expected to drive demand for these therapies in treating both oncological and non-oncological disorders. To meet this growing demand, various stakeholders have forged several alliances in the past few years.
These partnerships have enabled stakeholders to enhance their existing capabilities in terms of drug and technology portfolios to consolidate their presence in the targeted protein degradation industry. It is worth mentioning that research and development emerged as the most common type of partnership model adopted by the stakeholders in this domain.
Monetary assistance from angel investors, venture capitalists, and funding schemes of various public and private organizations / funds, along with assistance from regulatory authorities, have allowed targeted protein degradation companies to progress their R&D efforts in this domain. It is important to highlight that over USD 13.5 billion has been raised by the companies in this domain, since 2018. For instance, Kymera Therapeutics has raised a total of USD 517 million, till date, across four rounds of funding.
Stakeholders have filed or secured more than 985 patents related to targeted protein degradation in the last five years. Moreover, they have published over 385 articles on targeted protein degradation during the same period.
Researchers have registered around 250 clinical trials in this domain over the past few years, marking a notable rise in clinical activity. Most of these clinical trials are actively recruiting patients to evaluate targeted protein degradation therapies for HER2-Positive breast cancer, B cell lymphoma, and other conditions.
Driven by the ongoing pace of advancements in this field, growing collaborations, ample financial support from investors, rising number of patents and research articles, and encouraging clinical trial services and results, the targeted protein degradation market size is likely to witness significant growth during the forecast period.
The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders in the targeted protein degradation industry, across different geographies. Amongst other elements, the market report includes:
As industry advances toward overcoming the limitations of traditional drug therapies and intensifies research and development in targeted protein degradation technologies, the adoption of these innovative approaches is expected to increase. With continuous progress in the design of degrader, increasing investment, and encouraging results from ongoing clinical trials, the targeted protein degradation market is poised for substantial growth and enhanced adoption, paving the way for transformative changes in modern medicine.
Lead Author: Nishta Garg
Lead Reviewer: Dhriti Gulati
Chief Editor: Prachi Bhalla